

REMARKS

In response to the Restriction Requirement dated January 5, 2009, applicants have elected **hypertension** (claim 13) as one disease and **an antagonist to the sphingosine kinase expression product** (claim 23) as a modulating agent, for examination at this time. Applicants have amended claims 7, 20, 21, 23, 32, 45, 46, 47, and 48 to remove improper multiple dependencies. No new matter has been added by way of this amendment. Consideration of the elected claims is now requested.

Respectfully submitted,
SEED Intellectual Property Law Group PLLC

/William T. Christiansen/
William T. Christiansen, Ph.D.
Registration No. 44,614

WTC:jto

701 Fifth Avenue, Suite 5400
Seattle, Washington 98104
Phone: (206) 622-4900
Fax: (206) 682-6031
1422396_1.DOC